A SUCCESSFUL VACCINE AGAINST RESPIRATORY SYNCYTIAL VIRUS HAS BEEN DEVELOPED BY A COMPUTER

Respiratory syncytial virus (RSV) is the second leading cause of infant mortality after malaria worldwide.  It is the leading cause of pneumonia in children under one year of age. In general, this virus is very dangerous to all children under the age of three. The first-of-its-kind RSV vaccine candidate has been developed by artificial intelligence in an international project. As the first tests showed, the computer coped with this task much more successfully than human - the drug’s injection initiated the production of powerful neutralizing antibodies against RSV. Preliminary animal tests have shown that a "computer-assisted" respiratory syncytial virus vaccine elicits a stronger immune response against the virus than previous candidates created by human intelligence. The results of studies in mice and monkeys point the way to clinical trials in humans.

SOURCE: WORLDPHARMANEWS